Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RO7443904 |
| Trade Name | |
| Synonyms | RO-7443904|RO 7443904|RG6333|RG-6333|RG 6333 |
| Drug Descriptions |
RO7443904 is a bispecific antibody that targets both CD19 and CD28, resulting in cross-linking of CD28-positive T-cells to CD19-expressing tumor cells, potentially leading to enhanced cytotoxic response against CD19-positive tumor cells (NCI Drug Dictionary). |
| DrugClasses | CD19 Antibody 21 CD28 Antibody 12 |
| CAS Registry Number | NA |
| NCIT ID | C188312 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Glofitamab-gxbm + Obinutuzumab + RO7443904 | Glofitamab-gxbm Obinutuzumab RO7443904 | 0 | 1 |
| Glofitamab-gxbm + Obinutuzumab + RO7443904 + Tocilizumab | Glofitamab-gxbm Obinutuzumab RO7443904 Tocilizumab | 0 | 1 |
| Glofitamab-gxbm + RO7443904 | Glofitamab-gxbm RO7443904 | 0 | 0 |
| Glofitamab-gxbm + RO7443904 + Tocilizumab | Glofitamab-gxbm RO7443904 Tocilizumab | 0 | 0 |
| RO7443904 | RO7443904 | 0 | 0 |